Motor development in children prenatally exposed to selective serotonin reuptake inhibitors: a large population-based pregnancy cohort study

BJOG: An International Journal of Obstetrics and Gynaecology

Volumn 123, Issue 12, 2016, Pages 1908-1917

  Handal, M ^a   Skurtveit, S ^a,b   Furu, K ^a   Hernandez Diaz, S ^c   Skovlund, E ^a   Nystad, W ^a   Selmer, R ^a  

^a NORWEGIAN INSTITUTE OF PUBLIC HEALTH   (Norway)

^b UNIVERSITY OF OSLO   (Norway)

^c HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

Anxiety; cohort studies; depression; Norwegian Mother and Child Cohort study (MoBa); pregnancy; psychomotor disorder; selective serotonin reuptake inhibitors

Indexed keywords

SEROTONIN UPTAKE INHIBITOR;

ADULT; AGE; AGES AND STAGES QUESTIONNAIRE; ANXIETY DISORDER; ARTICLE; COHORT ANALYSIS; DISEASE ASSOCIATION; DISEASE SEVERITY; DRUG USE; EDUCATIONAL STATUS; FEMALE; GROSS AND FINE MOTOR MULLEN SCALE; HUMAN; MALE; MATERNAL SMOKING; MOTOR DEVELOPMENT; MOTOR FUNCTION TEST; OUTCOME ASSESSMENT; PARITY; PATERNAL AGE; POPULATION RESEARCH; PREGNANCY; PRENATAL EXPOSURE; PRIORITY JOURNAL; PROSPECTIVE STUDY; PUERPERAL DEPRESSION; QUESTIONNAIRE; SELF REPORT; SYMPTOM; CHEMICALLY INDUCED; COMPARATIVE STUDY; DEPRESSIVE DISORDER; INCIDENCE; MOTHER; MOTOR DISORDERS; NORWAY; PRESCHOOL CHILD; STATISTICS AND NUMERICAL DATA;

ADULT; CHILD, PRESCHOOL; COHORT STUDIES; DEPRESSIVE DISORDER; FEMALE; HUMANS; INCIDENCE; MOTHERS; MOTOR DISORDERS; NORWAY; PREGNANCY; PRENATAL EXPOSURE DELAYED EFFECTS; PROSPECTIVE STUDIES; SEROTONIN UPTAKE INHIBITORS; SURVEYS AND QUESTIONNAIRES;

EID: 84941670246     PISSN: 14700328     EISSN: 14710528     Source Type: Journal    
DOI: 10.1111/1471-0528.13582     Document Type: Article

References (27)

1. Davalos DB, Yadon CA, Tregellas HC. Untreated prenatal maternal depression and the potential risks to offspring: a review. ArchWomens Ment zHealth 2012;15:1–14.
2. Oyebode F, Rastogi A, Berrisford G, Coccia F. Psychotropics in pregnancy: safety and other considerations. Pharmacol Ther 2012;135:71–7.
3. El Marroun H, White T, Verhulst FC, Tiemeier H. Maternal use of antidepressant or anxiolytic medication during pregnancy and childhood neurodevelopmental outcomes: a systematic review. Eur Child Adolesc Psychiatry 2014;23:973–92.
4. Casper RC, Fleisher BE, Lee-Ancajas JC, Gilles A, Gaylor E, DeBattista A, et al. Follow-up of children of depressed mothers exposed or not exposed to antidepressant drugs during pregnancy. J Pediatr 2003;142:402–8.
5. Casper RC, Gilles AA, Fleisher BE, Baran J, Enns G, Lazzeroni LC. Length of prenatal exposure to selective serotonin reuptake inhibitor (SSRI) antidepressants: effects on neonatal adaptation and psychomotor development. Psychopharmacology 2011;217:211–9.
6. de Vries NK, van der Veere CN, Reijneveld SA, Bos AF. Early neurological outcome of young infants exposed to selective serotonin reuptake inhibitors during pregnancy: results from the observational SMOK study. PLoS ONE 2013;8:e64654.
7. Galbally M, Lewis AJ, Buist A. Developmental outcomes of children exposed to antidepressants in pregnancy. Aust N Z J Psychiatry 2011;45:393–9.
8. Pedersen LH, Henriksen TB, Olsen J. Fetal exposure to antidepressants and normal milestone development at 6 and 19 months of age. Pediatrics 2010;125:e600–8.
9. Kingston D, Tough S, Whitfield H. Prenatal and postpartum maternal psychological distress and infant development: a systematic review. Child Psychiatry Hum Dev 2012;43:683–714.
10. Magnus P, Irgens LM, Haug K, Nystad W, Skjaerven R, Stoltenberg C. Cohort profile: the Norwegian Mother and Child Cohort Study (MoBa). Int J Epidemiol 2006;35:1146–50.
11. Skurtveit S, Selmer R, Roth C, Hernandez-Diaz S, Handal M. Prenatal exposure to antidepressants and language competence at age three: results from a large population-based pregnancy cohort in Norway. BJOG 2014;121:1621–31.
12. Irgens LM. The Medical Birth Registry of Norway. Epidemiological research and surveillance throughout 30 years. Acta Obstet Gynecol Scand 2000;79:435–9.
13. Squires J, Twombly E, Bricker D, Potter L. Ages and Stages Questionnaires User's Guide, 3rd edn. Baltimore, London, Sydney: Paul H Brookes Publishing Co., 2009.
14. Squires J, Bricker D, Potter L. Revision of a parent-completed development screening tool: ages and Stages Questionnaires. J Pediatr Psychol 1997;22:313–28.
15. Stoltenberg C, Schjolberg S, Bresnahan M, Hornig M, Hirtz D, Dahl C, et al. The Autism Birth Cohort: a paradigm for gene-environment-timing research. Mol Psychiatry 2010;15:676–80.
16. Skurtveit S, Selmer R, Odsbu I, Handal M. Self-reported data on medicine use in the Norwegian Mother and Child cohort study compared to data from the Norwegian Prescription Database. Nor Epidemiol 2014;24:8.
17. Skurtveit S, Selmer R, Tverdal A, Furu K, Nystad W, Handal M. Drug exposure: inclusion of dispensed drugs before pregnancy may lead to underestimation of risk associations. J Clin Epidemiol 2013;66:964–72.
18. Nilsen RM, Vollset SE, Gjessing HK, Skjaerven R, Melve KK, Schreuder P, et al. Self-selection and bias in a large prospective pregnancy cohort in Norway. Paediatr Perinat Epidemiol 2009;23:597–608.
19. Strand BH, Dalgard OS, Tambs K, Rognerud M. Measuring the mental health status of the Norwegian population: a comparison of the instruments SCL-25, SCL-10, SCL-5 and MHI-5 (SF-36). Nord J Psychiatry 2003;57:113–8.
20. Herlenius E, Lagercrantz H. Neurotransmitters and neuromodulators during early human development. Early Hum Dev 2001;65:21–37.
21. Lee LJ. Neonatal fluoxetine exposure affects the neuronal structure in the somatosensory cortex and somatosensory-related behaviors in adolescent rats. Neurotox Res 2009;15:212–23.
22. Maciag D, Simpson KL, Coppinger D, Lu Y, Wang Y, Lin RC, et al. Neonatal antidepressant exposure has lasting effects on behavior and serotonin circuitry. Neuropsychopharmacology 2006;31:47–57.
23. Austin MP, Karatas JC, Mishra P, Christl B, Kennedy D, Oei J. Infant neurodevelopment following in utero exposure to antidepressant medication. Acta Paediatr 2013;102:1054–9.
24. Gentile S, Galbally M. Prenatal exposure to antidepressant medications and neurodevelopmental outcomes: a systematic review. J Affect Disord 2011;128:1–9.
25. Nulman I, Rovet J, Stewart DE, Wolpin J, Pace-Asciak P, Shuhaiber S, et al. Child development following exposure to tricyclic antidepressants or fluoxetine throughout fetal life: a prospective, controlled study. Am J Psychiatry 2002;159:1889–95.
26. Suri R, Hellemann G, Stowe ZN, Cohen LS, Aquino A, Altshuler LL. A prospective, naturalistic, blinded study of early neurobehavioral outcomes for infants following prenatal antidepressant exposure. J Clin Psychiatry 2011;72:1002–7.
27. Yaris F, Kadioglu M, Kesim M, Ulku C, Yaris E, Kalyoncu NI, et al. Newer antidepressants in pregnancy: prospective outcome of a case series. Reprod Toxicol 2004;19:235–8.